Tirofiban for the treatment of ischaemic stroke
Tirofiban is one of three glycoprotein IIb/IIIa receptor antagonists approved by the US FDA, beside abciximab and eptifibatide. The approval of tirofiban covers conservative treatment of myocardial infarction and unstable angina, as well as percutaneous coronary intervention, for which treatment wit...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2006
|
| In: |
Expert opinion on pharmacotherapy
Year: 2006, Jahrgang: 7, Heft: 1, Pages: 73-79 |
| ISSN: | 1744-7666 |
| DOI: | 10.1517/14656566.7.1.73 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1517/14656566.7.1.73
|
| Verfasserangaben: | Simone C. Bukow, Michael Daffertshofer, Michael G. Hennerici |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1801205078 | ||
| 003 | DE-627 | ||
| 005 | 20230427140255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220509s2006 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/14656566.7.1.73 |2 doi | |
| 035 | |a (DE-627)1801205078 | ||
| 035 | |a (DE-599)KXP1801205078 | ||
| 035 | |a (OCoLC)1341459771 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bukow, Simone |e VerfasserIn |0 (DE-588)1257106678 |0 (DE-627)1801206627 |4 aut | |
| 245 | 1 | 0 | |a Tirofiban for the treatment of ischaemic stroke |c Simone C. Bukow, Michael Daffertshofer, Michael G. Hennerici |
| 264 | 1 | |c 2006 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 22 December 2005 | ||
| 500 | |a Gesehen am 09.05.2022 | ||
| 520 | |a Tirofiban is one of three glycoprotein IIb/IIIa receptor antagonists approved by the US FDA, beside abciximab and eptifibatide. The approval of tirofiban covers conservative treatment of myocardial infarction and unstable angina, as well as percutaneous coronary intervention, for which treatment with tirofiban is recommended in moderate-to-high-risk patients. The efficacy of glycoprotein IIb/IIIa antagonists in myocardial infarction indicated that these agents may also be helpful in the treatment of acute ischaemic stroke. Although experimental data are lacking, observational studies are promising. In recent years, increasing effort in studying glycoprotein IIb/IIIa antagonists has been made, mostly for treatment with abciximab. However, there is one Phase II trial that investigated treatment with tirofiban. | ||
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Brain Ischemia | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Platelet Glycoprotein GPIIb-IIIa Complex | |
| 650 | 4 | |a Stroke | |
| 650 | 4 | |a Tirofiban | |
| 650 | 4 | |a Tyrosine | |
| 700 | 1 | |a Daffertshofer, Michael |e VerfasserIn |0 (DE-588)1206109661 |0 (DE-627)1691876909 |4 aut | |
| 700 | 1 | |a Hennerici, Michael G. |d 1948- |e VerfasserIn |0 (DE-588)11587545X |0 (DE-627)077527704 |0 (DE-576)290126444 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d Abingdon, Oxon : Routledge, Taylor & Francis, 1999 |g 7(2006), 1, Seite 73-79 |h Online-Ressource |w (DE-627)324741901 |w (DE-600)2030119-4 |w (DE-576)302969330 |x 1744-7666 |7 nnas |a Tirofiban for the treatment of ischaemic stroke |
| 773 | 1 | 8 | |g volume:7 |g year:2006 |g number:1 |g pages:73-79 |g extent:7 |a Tirofiban for the treatment of ischaemic stroke |
| 856 | 4 | 0 | |u https://doi.org/10.1517/14656566.7.1.73 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220509 | ||
| 993 | |a Article | ||
| 994 | |a 2006 | ||
| 998 | |g 11587545X |a Hennerici, Michael G. |m 11587545X:Hennerici, Michael G. |d 60000 |d 62700 |d 60000 |e 60000PH11587545X |e 62700PH11587545X |e 60000PH11587545X |k 0/60000/ |k 1/60000/62700/ |k 0/60000/ |p 3 |y j | ||
| 998 | |g 1206109661 |a Daffertshofer, Michael |m 1206109661:Daffertshofer, Michael |d 60000 |e 60000PD1206109661 |k 0/60000/ |p 2 | ||
| 998 | |g 1257106678 |a Bukow, Simone |m 1257106678:Bukow, Simone |d 60000 |d 62700 |e 60000PB1257106678 |e 62700PB1257106678 |k 0/60000/ |k 1/60000/62700/ |p 1 |x j | ||
| 999 | |a KXP-PPN1801205078 |e 4130333577 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Tirofiban for the treatment of ischaemic stroke","title":"Tirofiban for the treatment of ischaemic stroke"}],"person":[{"family":"Bukow","given":"Simone","roleDisplay":"VerfasserIn","display":"Bukow, Simone","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Daffertshofer, Michael","given":"Michael","family":"Daffertshofer"},{"given":"Michael G.","family":"Hennerici","role":"aut","display":"Hennerici, Michael G.","roleDisplay":"VerfasserIn"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Published online: 22 December 2005","Gesehen am 09.05.2022"],"language":["eng"],"recId":"1801205078","origin":[{"dateIssuedDisp":"2006","dateIssuedKey":"2006"}],"id":{"doi":["10.1517/14656566.7.1.73"],"eki":["1801205078"]},"name":{"displayForm":["Simone C. Bukow, Michael Daffertshofer, Michael G. Hennerici"]},"physDesc":[{"extent":"7 S."}],"relHost":[{"titleAlt":[{"title":"EOP"}],"part":{"extent":"7","text":"7(2006), 1, Seite 73-79","volume":"7","issue":"1","pages":"73-79","year":"2006"},"pubHistory":["1.1999/2000 -"],"recId":"324741901","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Tirofiban for the treatment of ischaemic strokeExpert opinion on pharmacotherapy","title":[{"subtitle":"EOP","title":"Expert opinion on pharmacotherapy","title_sort":"Expert opinion on pharmacotherapy"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1744-7666"],"eki":["324741901"],"zdb":["2030119-4"]},"origin":[{"publisherPlace":"Abingdon, Oxon ; London [u.a.]","dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisher":"Routledge, Taylor & Francis ; Informa Healthcare"}]}]} | ||
| SRT | |a BUKOWSIMONTIROFIBANF2006 | ||